PBM Bathi resik saben saham (EPS TTM) Psyence Biomedical Limited

Psyence Biomedical Ltd. (PBM) is researching the application of psilocybin in palliative therapy for cancer and depressed patients. The change in the rolling annual EPS on the GURU.Markets portal reflects income dynamics, where the value 0.00 captures the metric level. However, patent protection for exclusive medical pricing power contrasts with the search for funding for Canadian base metal exploration, which excludes standard M&A deals.

Efficient supply logistics for remote drilling sites of Psyence Biomedical Ltd. (PBM) ensure the continuity of resource exploration. This metric is calculated as the ratio of annual net profit to the total number of shares, isolating equity income from the impact of issuance. Investors utilize this parameter to assess the real profitability of the business per share. Stable values confirm resilience to external shocks. The price action of the company's specific annual income indicator allows for the identification of hidden stagnation or growth potential.